Login to Your Account



financings NEWS
It's been more than six years since 2007 start-up Vaccinogen Inc. licensed rights to Oncovax, a cancer vaccine set to start a confirmatory phase III study in colon cancer.
DUALING DRUGS TO MEET AT HIGH NOON?

The $49.5 million initial public offering (IPO) by drug-device maker Zosano Pharma Corp. was modest by comparison to 2014 blockbusters by the likes of Juno Therapeutics Inc. and Kite Pharma Inc.

Zafgen Inc.'s shares (NASDAQ:ZFGN) rose 5 percent to $38.97 Friday as the company priced a public offering of about 3.9 million shares at $35 each.
More financings Headlines

Cast Your Vote

Has biotech’s bubble burst?: